Abstract | BACKGROUND AND OBJECTIVE: PATIENTS AND METHODS: RESULTS: No drug- or injection-related adverse events and no serious adverse events were reported. At 6 and 12 months, 4 and 5 patients gained 3 or more lines of VA, respectively; 3 patients lost less than 3 lines of VA at 6 months, and 6 patients lost less than 3 lines at 12 months. At 6 and 12 months, VA increased by a mean (± standard error of the mean) of 2.06 ± 1.23 and 1.17 ± 0.62 lines, respectively. Central retinal thickness decreased by a mean of 62.65 ± 22.46 and 62.16 ± 29.20 μm at months 6 and 12, respectively. When stratified by pigment epithelial detachment (PED) status, patients without PED had better visual and anatomical outcomes than patients with PED. CONCLUSION:
|
Authors | Richard S Kaiser, Omesh P Gupta, Carl D Regillo, Allen C Ho, Mitchell S Fineman, James F Vander, J Arch McNamara, Gary C Brown |
Journal | Ophthalmic surgery, lasers & imaging : the official journal of the International Society for Imaging in the Eye
(Ophthalmic Surg Lasers Imaging)
2012 Jan-Feb
Vol. 43
Issue 1
Pg. 13-9
ISSN: 1938-2375 [Electronic] United States |
PMID | 21986085
(Publication Type: Clinical Trial, Phase I, Clinical Trial, Phase II, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2012, SLACK Incorporated. |
Chemical References |
- Angiogenesis Inhibitors
- Antibodies, Monoclonal, Humanized
- Aptamers, Nucleotide
- VEGFA protein, human
- Vascular Endothelial Growth Factor A
- pegaptanib
- Bevacizumab
- Ranibizumab
|
Topics |
- Aged
- Aged, 80 and over
- Angiogenesis Inhibitors
(therapeutic use)
- Antibodies, Monoclonal, Humanized
(adverse effects, therapeutic use)
- Aptamers, Nucleotide
(therapeutic use)
- Bevacizumab
- Drug Substitution
- Female
- Humans
- Intravitreal Injections
- Male
- Middle Aged
- Ranibizumab
- Retreatment
- Tomography, Optical Coherence
- Treatment Failure
- Treatment Outcome
- Vascular Endothelial Growth Factor A
(antagonists & inhibitors)
- Visual Acuity
(physiology)
- Wet Macular Degeneration
(drug therapy, physiopathology)
|